|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2011-7-18
|
|
pubmed:abstractText |
Prolonged administration of methyl transferase inhibitors may increase response rates in myelodysplastic syndromes (MDS). Fourteen MDS patients with anemia and less than 10% marrow blasts received azacitidine 50 mg/m(2) thrice weekly for 2 weeks every 4 weeks; 7 also received weekly erythropoietin. The response rate of 43% did not improve the rates reported with other azacitidine administration schedules, so the study was closed. A decreased apoptosis of primitive erythroid progenitors and increased expression of BclX(L) was observed with treatment in responding patients compared to non-responders. Azacitidine may modulate BclX(L) and improve erythropoiesis through reduction of apoptosis in primitive erythroid progenitor population in MDS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1873-5835
|
|
pubmed:author |
pubmed-author:ChanEdward MEM,
pubmed-author:ChanRebecca JRJ,
pubmed-author:CripeLarry DLD,
pubmed-author:HoodDanielD,
pubmed-author:HuiChua LinCL,
pubmed-author:KohlbacherKristopher JKJ,
pubmed-author:NabingerSarah CSC,
pubmed-author:OrschellChristie MCM,
pubmed-author:PlettArturA,
pubmed-author:SampsonCarolC,
pubmed-author:SayarHamidH,
pubmed-author:WalterAmandaA,
pubmed-author:WestEvan SES,
pubmed-author:WuJingweiJ,
pubmed-author:YangZhenyunZ,
pubmed-author:YuZhangshengZ
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1108-10
|
|
pubmed:meshHeading |
pubmed-meshheading:21420732-Aged,
pubmed-meshheading:21420732-Aged, 80 and over,
pubmed-meshheading:21420732-Anemia,
pubmed-meshheading:21420732-Antimetabolites, Antineoplastic,
pubmed-meshheading:21420732-Apoptosis,
pubmed-meshheading:21420732-Azacitidine,
pubmed-meshheading:21420732-Erythroid Precursor Cells,
pubmed-meshheading:21420732-Erythropoiesis,
pubmed-meshheading:21420732-Erythropoietin,
pubmed-meshheading:21420732-Female,
pubmed-meshheading:21420732-Flow Cytometry,
pubmed-meshheading:21420732-Humans,
pubmed-meshheading:21420732-Male,
pubmed-meshheading:21420732-Middle Aged,
pubmed-meshheading:21420732-Myelodysplastic Syndromes,
pubmed-meshheading:21420732-Prognosis,
pubmed-meshheading:21420732-bcl-X Protein
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
|
|
pubmed:affiliation |
Division of Hematology and Oncology, Department of Medicine, Indiana University Simon Cancer Center, Indianapolis, IN 46202, USA. ssayar@iupui.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
